Dental pulp disorder
diseaseOn this page
Also known as dental pulp diseasedental pulp disease or disorderdisease of dental pulpdisease or disorder of dental pulpdisorder of dental pulp
Summary
Dental pulp disorder (MONDO:0003394) is a disease (an umbrella term covering 7 Mondo subtypes) with 5 GWAS associations across 8 studies and 26 clinical trials. Top therapeutic interventions include articaine, lidocaine, and ferric sulfate. A subtype of tooth disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 7 Mondo subtypes
- GWAS associations: 5
- Clinical trials: 26
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | dental pulp disorder |
| Mondo ID | MONDO:0003394 |
| EFO | EFO:0009540 |
| MeSH | D003788 |
| DOID | DOID:5330 |
| NCIT | C34530 |
| SNOMED CT | 57203004 |
| UMLS | C0011405 |
| MedGen | 8305 |
| Anatomy (UBERON) | UBERON:0001754 |
| Is cancer (heuristic) | no |
Also known as: dental pulp disease · dental pulp disease or disorder · dental pulp disorder · disease of dental pulp · disease or disorder of dental pulp · disorder of dental pulp
Data availability: 5 GWAS associations (8 studies).
Disease family
This is a subtype of tooth disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › tooth disorder › dental pulp disorder
Related subtypes (10): dental abscess, tooth hard tissue disease, tooth erosion, non-bacterial, tooth agenesis, dental fluorosis, anodontia, taurodontism, dentinogenesis imperfecta, odontogenic neoplasm, dental radicular dysplasia
Subtypes (7): pulp degeneration, dental pulp necrosis, pulp erosion, dental pulp calcification, pulpitis, exposure, dental pulp, secondary dentine
Genetics & variants
GWAS landscape
5 GWAS associations across 8 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs9614155 | 7e-10 | HORMAD2 - LIF-AS1 | ? | 0.94 |
| rs747852970 | 5e-09 | DUXAP11 - APOOP5 | ? | 2.21 |
| rs183067431 | 3e-08 | SPATA2P1 - RN7SKP6 | ? | |
| rs67798578 | 4e-08 | SLC8A1 - LINC01794 | ? | |
| 6p22-p21 | 5e-07 | ? | 2.61 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90269794 | Saarentaus EC | 2023 | 48,687 | 211,718 | Inflammatory and infectious upper respiratory diseases associate with 41 genomic loci and type 2 inflammation. |
| GCST90473756 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 7,734 | 450,706 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90080168 | Backman JD | 2021 | 3,161 | 381,325 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90084154 | Backman JD | 2021 | 3,161 | 381,325 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90651673 | Liu TY | 2025 | 2,759 | 208,919 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90651626 | Liu TY | 2025 | 2,019 | 208,919 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90726971 | Kim HI | 2026 | 1,464 | 42,562 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
| GCST90044100 | Jiang L | 2021 | 532 | 455,816 | A generalized linear mixed model association tool for biobank-scale data. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 5 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 2 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 3 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 2 |
| intergenic_variant | 2 |
| unknown | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs9614155 | 22 | 30186009 | G>A,C,T | 0.05 | intron_variant | HORMAD2 - LIF-AS1 | 7e-10 | Tier 4: intronic/intergenic |
| rs747852970 | 16 | 59708933 | G>A,C,T | intergenic_variant | DUXAP11 - APOOP5 | 5e-09 | Tier 4: intronic/intergenic | |
| rs183067431 | 13 | 56761062 | A>T | intergenic_variant | SPATA2P1 - RN7SKP6 | 3e-08 | Tier 4: intronic/intergenic | |
| rs67798578 | 2 | 40706995 | C>T | 0.05 | intron_variant | SLC8A1 - LINC01794 | 4e-08 | Tier 4: intronic/intergenic |
| 6p22-p21 | 5e-07 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Propolis Wax.
Clinical trials & evidence
Clinical trials
Clinical trials: 26.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 21 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02286648 | PHASE4 | UNKNOWN | Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars |
| NCT02702505 | PHASE4 | UNKNOWN | Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT |
| NCT03376984 | PHASE2/PHASE3 | WITHDRAWN | Nanodiamond-Gutta Percha Composite Biomaterials for Root Canal Therapy |
| NCT07541976 | PHASE2 | ACTIVE_NOT_RECRUITING | Comparative Evaluation of Three Different Pulpotomy Agents in Primary Molars |
| NCT02137967 | EARLY_PHASE1 | UNKNOWN | Sodium Hypochlorite Pulpotomies in Primary Molars: Comparison With Conventional 20% Formocresol Pulpotomies |
| NCT02636504 | Not specified | NOT_YET_RECRUITING | Evaluation of Three Pulp Vitality Tests |
| NCT06675058 | Not specified | NOT_YET_RECRUITING | Caries Location and Its Effect on the Success Rate of Indirect Pulp Treatment in Primary Molars |
| NCT07073573 | Not specified | ACTIVE_NOT_RECRUITING | Evaluation of Pulpal Biomarkers in Vital Pulp Therapy |
| NCT07102121 | Not specified | ENROLLING_BY_INVITATION | Comparison of Post Cementation Sensitivity Between RMGIC and GIC as Luting Materials in a Randomized Clinical Trial |
| NCT07291531 | Not specified | NOT_YET_RECRUITING | Optimizing Pulp Management in Autotransplantation of Mature Third Molars: A Randomized Controlled Trial |
| NCT00575263 | Not specified | COMPLETED | Sodium Channel Expression in Human Teeth |
| NCT00595595 | Not specified | COMPLETED | Development of a Model to Evaluate Regenerative Endodontic Techniques Using Extract Human Teeth |
| NCT02521909 | Not specified | COMPLETED | Accuracy of Electronic Apex Locators ProMark, RootZX II and NRG Rider on Working Length of Multi-rooted Teeth |
| NCT02698163 | Not specified | COMPLETED | Nanodiamond Modified Gutta Percha (NDGP) Composite for Non-surgical Root Canal Therapy (RCT) Filler Material |
| NCT02819258 | Not specified | COMPLETED | Monocentric Study and Prognostic of Treatments Endodontics of Teeth With Periapical Pathology Realized CSERD (Nantes University Hospital) |
| NCT03378778 | Not specified | COMPLETED | Survival of Root Canal Treated Teeth Restored With Ceramic Onlays |
| NCT03652129 | Not specified | COMPLETED | Digitized Assessment for the Survival of Mature Anterior Teeth With Periapical Lesion After One Step Regenerative Approach Using Different Asepsis Maneuvers |
| NCT04385693 | Not specified | COMPLETED | Intentional Pulpotomy to Preserve Hopeless Molars |
| NCT04636450 | Not specified | UNKNOWN | Manual and Rotatory Instrumentation Pulpectomy in Primary Mandibular Molars |
| NCT04942158 | Not specified | COMPLETED | Non-instrumentation Root Canal Treatment of Primary Molars |
| NCT05310500 | Not specified | COMPLETED | Comparative Evaluation of Impact of Sodium Hypochlorite on the Physical Properties of Protaper Gold and Dia-X ProTaper. |
| NCT05555563 | Not specified | COMPLETED | Effect of MTAD on The Outcome of Primary Root Canal Treatment |
| NCT05944341 | Not specified | UNKNOWN | Articaine Efficiency in Pulpectomy of Children With Irreversible Pulpitis Under the Age of Four |
| NCT06606236 | Not specified | COMPLETED | Neuropeptide Y Regulates Neurogenic Pulp Inflammation |
| NCT06795282 | Not specified | COMPLETED | Post Operative Sensitivity of MTA Obturation |
| NCT07434622 | Not specified | COMPLETED | Diagnostic Accuracy of Cold, Heat, and Electric Pulp Tests |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ARTICAINE | 4 | 1 |
| LIDOCAINE | 4 | 1 |
| FERRIC SULFATE | 3 | 1 |
| GUTTA PERCHA | -1 | 2 |